COVID-19: We are currently offering vaccinations to current qualifying patients. CURRENT PATIENTS VACCINATION INFO.

Clinical Category: Lung Cancer

A Phase I/II Open-Label, Safety And Preliminary Efficacy Study Of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors (NSCLC, RCC, Bladder, Breast triple negative)
Monika Chaudhry | June 19, 2021

BO42592
Monika Chaudhry | April 4, 2021

CA224 104
Monika Chaudhry | April 4, 2021

4D Pharma MRx0518
Monika Chaudhry | February 10, 2020